IBC
19.9.2018 12:05:11 CEST | Business Wire | Press release
IBC2018 has closed its doors for this year and has delivered another great event with visitor figures of 55,884. As well as providing a host of new initiatives this year, the exhibition grew by 667m2 and conference delegates were up by 14% year on year. One of the most important growth figures lies in the diversity of its content with a targeted effort increasing women speakers at the conference up from 14% to 37%.
The IBC International Honour for Excellence saw its first-ever woman recipient this year, too. Joan Ganz Cooney was the co-creator of the global phenomenon that is Sesame Street , 50 years ago and her trophy was collected on her behalf by one of the street’s longest residents, Ernie.
The IBC App has provided real networking opportunities, with more than 91,000 interactions on the matchmaking platform. In addition, IBC trended number one on Twitter in the Netherlands on several days of the convention, with 185 million potential impressions and over 250,000 video views. Engagement with IBC has also increased on a year-round basis with IBC365 – the site now has over 55,000 subscribers averaging 49,000 active users per month.
Michael Crimp, IBC’s CEO, comments; “The show is about engagement, engagement, engagement. The stats are up in almost all areas and re-bookings are ahead of last year. IBC is much more than a trade show, we have developed a basket of data-driven statistics including sales leads generated on stands, conference attendance and IBC365 views and this sharing of information is pivotal to the longevity of IBC’s success and sits at the core of the organisation.”
“All of the initiatives this year have been aimed at bringing together the best minds, the original thinkers, to network and share their knowledge. As all communication becomes video and audio, IBC continues to be the place to debate the future of media, technology and entertainment,” adds Crimp.
Guiding the renewed focus this year was a new content steering group, drawn from across the industry, and chaired by Keith Underwood, Chief Operating Officer at Channel 4 in the UK.
IBC head of content Jaisica Lapsiwala, said, “This year, we have worked closely with the industry to create a programme that is not only reflective of the changes in the ecosystem, but which also paves a path forward for our industry. This has resulted in an engaging and diverse 2018 edition of IBC. An example of this was our Global Gamechangers day which brought creative, technology and business chiefs such as Zahra Rasool from Al Jazeera, Peter Salmon from Endemol and Lindsay Pattison from WPP to the stage. Threaded through the programme were the cutting-edge technologies transforming the industry. Blockchain is a great example, with a keynote from Kim Jackson of Singular DTV and papers from people who are already implementing it, like Éric Minoli of Groupe Média TFO.”
Alongside the conference, IBC hosted three invitation-only executive forums. The Leaders’ Forum looked to the future, considering what the new ecosystem could be following consolidation, acquisition and collaboration. The Cyber Security Forum considered not just the threats but how to respond to them. New to the programme this year was the Telco and Media Innovation Forum, a vital point of debate as the boundaries between media and communication blur.
Once again, IBC was the venue for an examination of the intersection of craft and technology in The Big Screen. Sessions included an in-depth look at the effects in Game of Thrones and Pixar’s Dominic Glynn talking about the animation marvel that is The Incredibles 2 – and how things have changed in the 14 years since the original movie.
The Future Zone is always a busy part of IBC, with presentations from researchers and academic bodies developing the ideas which may become the hit products five years from now. This year saw the addition of a theatre stage, presented by one of IBC’s owners, IABM, with a rolling programme of presentations discussing the ideas in more detail.
As well as the IBC Big Screen, the IABM Future Trends Theatre and the Content Everywhere Hub, staged presentations and enlarged on-stand meeting areas are becoming an increasingly common feature of exhibition stands throughout the show. “As the industry has moved on from big boxes handling discrete functions towards a software-based world that looks across the content supply chain, so the way vendors present themselves and interact with visitors at IBC has changed,” said Roger Thornton, chair of the IBC exhibition committee.
“Today, it’s all about collaboration to deliver solutions that give broadcast and media companies the agility and flexibility they need to keep ahead in this rapidly transforming media landscape. That’s why we’re seeing more and more companies using big-picture theatre presentations on their stands and providing large meeting areas where the conversations that kick off the collaboration get started.”
IBC2019 starts with the first day of conference sessions on Thursday 12 September, running until the exhibition closes on Tuesday 17 September.
-ENDS-
Notes to Editors:
About IBC
IBC is the world’s most influential media,
entertainment and technology show, attracting 55,000+ attendees from
more than 170 countries and combining a highly respected and
peer-reviewed conference with an exhibition that showcases 1,700+
leading industry suppliers of state-of-the-art technology. In addition
to the world-class exhibition and conference, IBC also encompasses the
IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
IBC2019 Dates
| Conference: | 12 - 16 September 2019 | ||||
| Exhibition: | 13 - 17 September 2019 |
For more information about IBC2019 visit: show.ibc.org/
View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005306/en/
Contact:
Bubble Agency Louise Wells E: louisew@bubbleagency.com T: +44 7718 985 252
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
